Acalabrutinib vs. ibrutinib: How do they compare?

Drugs.com

Official answer

by Drugs.com

Acalabrutinib, a treatment for chronic lymphocytic leukemia (CLL), appears to have a lower risk of adverse events (such as atrial fibrillation) in comparison to ibrutinib. A 2021 phase III study in the Journal of Clinical Oncology found that while both medications have similar efficacy, acalabrutinib was better tolerated with fewer side effects. In clinical studies:

  • In comparison to ibrutinib, acalabrutinib was associated with an overall lower occurrence rate of hypertension, diarrhea, arthralgia, atrial fibrillation, back pain, urinary tract infection, muscle spasms, bruising and indigestion.
  • In comparison to ibrutinib, acalabrutinib was associated with an overall higher occurrence rate of headache, cough and fatigue.
  • A grade 3 or higher infection developed similarly for both drugs: 30% of ibrutinib patients in comparison to 30.8% of acalabrutinib patients developed these infections.
  • The most common serious side effects for both acalabrutinib and ibrutinib were found to be anemia, pneumonia and atrial fibrillation.

    • Researchers have found that acalabrutinib is a more selective Bruton’s tyrosine kinase (BTK) inhibitor. The way that both acalabrutinib and ibrutinib work is by irreversibly binding to and destroying the cancerous B lymphocytes. Acalabrutinib’s increased selectivity means that the risk of off-target cells, or noncancerous cells, is much lower than in ibrutinib, which thus results in a lower risk of adverse effects.

    Related medical questions

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords